The UK has an incredible opportunity to improve patients’ lives through cannabis-based medicines for some of the most debilitating conditions, such as chronic pain. Celadon Pharmaceuticals Plc is at the forefront of building this new pharmaceutical sector. We have a simple approach: high-quality UK cultivation and API manufacturing, clinical trials, and R&D into cannabinoids. We …
Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include: – The completion of seven harvests of high THC cannabis – Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence – The commencement …
We are delighted to feature in BusinessCann today. Read the full article here: https://businesscann.com/celadon-pharma-says-it-wants-to-deliver-its-trial-and-product-as-a-holistic-package-overseas-amid-first-update-since-aim-listing/
Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m. Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and …
Input your search keywords and press Enter.